vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
Ceribell, Inc. is the larger business by last-quarter revenue ($24.8M vs $16.2M, roughly 1.5× DNA X, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -54.6%, a 25.3% gap on every dollar of revenue.
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
CBLL vs SONM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $16.2M |
| Net Profit | $-13.5M | $-4.8M |
| Gross Margin | 87.3% | 11.2% |
| Operating Margin | -58.9% | -24.5% |
| Net Margin | -54.6% | -29.3% |
| Revenue YoY | — | 7.9% |
| Net Profit YoY | — | -89.2% |
| EPS (diluted) | $-0.35 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | — | ||
| Q3 25 | $22.6M | $16.2M | ||
| Q2 25 | $21.2M | $11.2M | ||
| Q1 25 | $20.5M | $16.7M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | $17.2M | $15.0M | ||
| Q2 24 | — | $11.5M | ||
| Q1 24 | — | $9.1M |
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-13.5M | $-4.8M | ||
| Q2 25 | $-13.6M | $-7.5M | ||
| Q1 25 | $-12.8M | $458.0K | ||
| Q4 24 | — | $-21.6M | ||
| Q3 24 | $-10.4M | $-2.5M | ||
| Q2 24 | — | $-6.6M | ||
| Q1 24 | — | $-2.9M |
| Q4 25 | 87.3% | — | ||
| Q3 25 | 88.3% | 11.2% | ||
| Q2 25 | 88.1% | 7.6% | ||
| Q1 25 | 87.9% | 50.0% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | 87.3% | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | — | 31.8% |
| Q4 25 | -58.9% | — | ||
| Q3 25 | -64.8% | -24.5% | ||
| Q2 25 | -70.5% | -60.2% | ||
| Q1 25 | -69.3% | 3.9% | ||
| Q4 24 | — | 55.3% | ||
| Q3 24 | -57.8% | -15.8% | ||
| Q2 24 | — | -56.2% | ||
| Q1 24 | — | -29.5% |
| Q4 25 | -54.6% | — | ||
| Q3 25 | -59.6% | -29.3% | ||
| Q2 25 | -64.4% | -66.8% | ||
| Q1 25 | -62.4% | 2.7% | ||
| Q4 24 | — | -141.6% | ||
| Q3 24 | -60.6% | -16.7% | ||
| Q2 24 | — | -57.5% | ||
| Q1 24 | — | -31.9% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.37 | $-4.83 | ||
| Q2 25 | $-0.38 | $-0.79 | ||
| Q1 25 | $-0.36 | $0.08 | ||
| Q4 24 | — | $-116.99 | ||
| Q3 24 | $-1.85 | $-9.32 | ||
| Q2 24 | — | $-1.41 | ||
| Q1 24 | — | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $155.3M | $-701.0K |
| Total Assets | $195.8M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | — | ||
| Q3 25 | $168.5M | $2.1M | ||
| Q2 25 | $177.4M | $2.0M | ||
| Q1 25 | $182.7M | $2.1M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $14.1M | $9.1M | ||
| Q2 24 | — | $9.6M | ||
| Q1 24 | — | $9.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $155.3M | — | ||
| Q3 25 | $164.1M | $-701.0K | ||
| Q2 25 | $172.2M | $-1.3M | ||
| Q1 25 | $180.9M | $-1.1M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | $-136.0M | $15.3M | ||
| Q2 24 | — | $17.5M | ||
| Q1 24 | — | $19.8M |
| Q4 25 | $195.8M | — | ||
| Q3 25 | $199.5M | $40.2M | ||
| Q2 25 | $207.7M | $36.1M | ||
| Q1 25 | $213.5M | $36.0M | ||
| Q4 24 | — | $39.7M | ||
| Q3 24 | $47.1M | $49.1M | ||
| Q2 24 | — | $45.9M | ||
| Q1 24 | — | $42.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $-7.0M |
| Free Cash FlowOCF − Capex | $-11.0M | — |
| FCF MarginFCF / Revenue | -44.2% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | — | ||
| Q3 25 | $-11.1M | $-7.0M | ||
| Q2 25 | $-7.5M | $-4.9M | ||
| Q1 25 | $-11.4M | $-9.6M | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-417.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-168.0K |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $-11.5M | — | ||
| Q2 25 | $-7.6M | — | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-554.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-198.0K |
| Q4 25 | -44.2% | — | ||
| Q3 25 | -50.8% | — | ||
| Q2 25 | -35.9% | — | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | — | -29.6% | ||
| Q3 24 | — | -3.7% | ||
| Q2 24 | — | -29.8% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
SONM
Segment breakdown not available.
